Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?

Publisher： Karger

E-ISSN： 1421-9875|33|1|95-104

ISSN： 0257-2753

Source： Digestive Diseases, Vol.33, Iss.1, 2015-09, pp. : 95-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Innate immunity and inflammatory bowel disease: a review of clinical evidence and future application

By Katakura Kyoko   Watanabe Hiroshi   Ohira Hiromasa  

Clinical Journal of Gastroenterology, Vol. 6, Iss. 6, 2013-12 ,pp. : 415-419

Springer Publishing Company

Access to resources Recommend Favorite

Integrating Imaging into Clinical Practice in Inflammatory Bowel Disease

By  

Digestive Diseases, Vol. 33, Iss. 1, 2015-09 ,pp. : 37-43

Karger

Access to resources Recommend Favorite

Metabolomics in the Clinical Diagnosis of Inflammatory Bowel Disease

By  

Digestive Diseases, Vol. 33, Iss. 1, 2015-09 ,pp. : 2-10

Karger

Access to resources Recommend Favorite

Changes in the incidence of inflammatory bowel disease: what does it mean?

By Russel M.G.V.M.  

European Journal of Internal Medicine, Vol. 11, Iss. 4, 2000-08 ,pp. : 191-196

Elsevier

Access to resources Recommend Favorite

What Can We Learn from Epidemiological Studies in Inflammatory Bowel Disease?

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 69-73

Karger

Access to resources Recommend Favorite